

2026Q1 Results Presentation

May. 2026



INNOVATION



China's Leading Innovative Pharmaceutical Enterprise

R&D Capabilities

8

R&D platforms

5

R&D centers

2000+

R&D professionals

~200

Innovative drugs and
new formulations

Company's Position and Reputation

- Chinese enterprises rank **NO.448** — *The Fortune* China 500 List (2025)
- Global pharmaceutical companies rank **NO.48** — *Pharmaceutical Manager* magazine of the United States (2025)
- Global R&D pipeline rank **NO.15** — Citeline Pharmaceutical R&D Annual Review (2026)

Manufacturing and Commercialization Capabilities

- **10+** Production bases for pharmaceutical products, including biological agent, Nanoformulation and mRNA vaccine etc.
- **10000+** professional sales representatives
- Covers **35,000+** medical institutions, and **350,000+** pharmacies



2026Q1 Updates

Regulatory Updates

3 New drugs approved

- Clevidipine Injectable Emulsion
- Aripiprazole Injection
- Amphotericin B liposomes (Europe)

1 Breakthrough Therapy Designations:

- **SYS6010 (EGFR ADC)**
Advanced or metastatic ESCC



License-out

In 2026, **1** BD transaction has been completed, with a total amount of **18.5** billion US dollars.

In 26Q1, the Licence fee income of **146** million RMB was booked in.

Major Clinical Trial Progress

21 IND approvals : • China (14) | Overseas (7)

12 New pivotal clinical trials :

- **Anbenitamab injection (KN026) :**
Adjuvant treatment of HER2+ breast cancer
- **Anbenitamab repodatecan (JSKN003) :**
≥3L HER2+ Advanced colorectal cancer
- **SYS6010 (EGFR ADC) :**
2L ESCC
≥2L HER2- / EGFR + Breast cancer
2L EGFRwt Nsq-NSCLC
- **SYH2053 (PCSK9 SiRNA) :**
Primary hypercholesterolemia and mixed dyslipidemia
(Monotherapy/Combined) / Heterozygous familial hypercholesterolemia
- **SYS6093 (TSLP mAb) :**
Moderate to severe asthma / Chronic sinusitis with nasal polyps
- **Paclitaxel cationic liposomes for injection :**
Liver metastasis of colorectal cancer (arterial infusion)
- **Long-acting octreotide injection:**
Postoperative adjuvant treatment for pancreatic neuroendocrine tumors



2026 Data Read-out Plan



Accepted Data Read-out

- AACR finished**
SYS6010
EGFR ADC
 Nasopharyngeal carcinoma phase I - oral
- ASCO accepted**
Anbenitamab Injection
KN026
 breast cancer(Neoadjuvant) phase III – oral (LBA)
- ASCO accepted**
SYS6010
EGFR ADC
 Advanced solid tumor phase II - poster
- ASCO accepted**
SYS6010+SYH2051
EGFR ADC+ATM Inhibitor
 Advanced solid tumor phase Ib / II - online publication
- ICHNO finished**
SYS6043
B7-H3 ADC
 Nasopharyngeal carcinoma phase I - oral (LBA)
- ASCO accepted**
SYS6043
B7-H3 ADC
 Advanced solid tumor phase I / II - oral
- ASCO accepted**
SYS6010+SG001
EGFR ADC+PD-1 Inhibitor
 Esophageal cancer phase II - poster
- ASCO accepted**
Paclitaxel cationic liposomes
 Advanced solid tumor (Arterial infusion chemotherapy) IIT - online publication
- SGO finished**
SYS6043
B7-H3 ADC
 Gynecological tumor phase I - oral
- ASCO accepted**
SYS6002
Nectin-4 ADC
 Advanced solid tumor phase I - poster
- ESC accepted**
SYH2053
PCSK9 SiRNA
 Hyperlipidemia phase II



Data Read-out In plan

- ERS in plan**
SYS6093
TSLP
 Moderate to severe asthma phase II
- ESMO in plan**
SYS6090
PD-1/IL-15
 Advanced solid tumor phase I
- ESMO in plan**
SYS6043
B7-H3 ADC
 Breast cancer phase I
- ESMO in plan**
SYS6010
EGFR ADC
 2L EGFRmut NSCLC phase III
- ESMO in plan**
SYS6010
EGFR ADC
 Head and Neck Squamous Cell Carcinoma phase I
- ESMO in plan**
Anbenitamab Injection
KN026
 1L Breast cancer phase III
 Gastric cancer OS data update phase III

.....



ICHNO 2026

19 -21 March 2026 Seville, Spain

Drug Design

- Topoisomerase I inhibitor , DAR ~6
- Fcγ receptor effector silencing design and cleavable linker
- Bystander Effect


n (%)	8 mg/kg Q3W (n=31)	Overall (n=65)
TEAEs	31 (100)	64 (98.5)
TRAEs	31 (100)	63 (96.9)
≥Grade 3 TRAEs	21 (67.7)	37 (56.9)
TRAEs leading to dose reduction	5 (16.1)	5 (7.7)
TRAEs leading to treatment discontinuation	2 (6.5)	3 (4.6)
TRSAEs	8 (25.8)	16 (24.6)
TRAEs leading to death	1 (3.2)	1 (1.5)

	8 mg/kg Q3W (n=29)	Overall (n=61)
BOR, n (%)		
CR	0	0
PR	12 (41.4)	18 (29.5)
SD	10 (34.5)	25 (41.0)
PD	5 (17.2)	12 (19.7)
NE	2 (6.9)	6 (9.8)
ORR, 95%CI	41.4 (23.5, 61.1)	29.5 (18.5, 42.6)
DCR, 95%CI	75.9 (56.5, 89.7)	70.5 (57.4, 81.5)
mDoR, month, 95%CI	5.8 (1.5, NA)	4.4 (4.4, NA)
mPFS, month, 95%CI	6.3 (3.9, NA)	5.7 (3.9, 6.3)

- SYS6043 demonstrated durable anti-tumor activity in patients with nasopharyngeal carcinoma (NPC). Notably, the 8 mg/kg Q3W cohort showed more promising efficacy, with an ORR of 41.4%, DCR of 75.9%, mPFS of 6.3 months, and mDoR of 5.8 months.
- SYS6043 demonstrated a manageable safety profile. The most common treatment-related adverse events (TRAEs) were hematologic toxicities.



SYS6043 (B7-H3 ADC) Gynecological Tumor Data Read-out — SGO Oral Presentation



- SYS6043 demonstrated a manageable safety profile. The most common TRAEs were hematological toxicity and gastrointestinal toxicity.
- 6 mg/kg Q3W ≥Grade 3 TRAEs is 34.3%

SYS6043 shows durable anti-tumor activity in treated patients with gynecological tumors

Type of cancer	ORR	DCR	mPFS
Ovarian cancer (N=70)	45.7%	88.6%	8.3 months
Cervical cancer (N=39)	35.9%	82.1%	5.8 months
Endometrial cancer (N=21)	33.3%	81.0%	8.0 months

n (%)	Overall (n=142)	6 mg/kg Q3W (n=70)
TRAEs	141 (99.3)	70 (100)
≥Grade 3 TRAEs	54 (38.0)	24 (34.3)
TRAEs leading to death	1 (0.7)	0
TRAEs leading to treatment discontinuation	2 (1.4)	0
TRAEs leading to dose interruption	45 (31.7)	20 (28.6)
TRAEs leading to dose reduction	11 (7.7)	5 (7.1)




SYS6010 Single-agent Treatment for Nasopharyngeal Carcinoma — 2026AACR Oral Presentation



Phase I Study Results of SYS6010 Monotherapy in Patients with Recurrent or Metastatic Advanced Nasopharyngeal Carcinoma (NPC) Progressed after Immune Checkpoint Inhibitors and Platinum-based Chemotherapy (N=56)

n (%)	4.2 mg/kg (n=32)	4.8 mg/kg (n=22)	Total (n=54)
CR	1 (3.1)	0	1 (1.9)
PR	8 (25.0)	8 (36.4)	16 (29.6)
SD	20 (62.5)	10 (45.5)	30 (55.6)
PD	3 (9.4)	4 (18.2)	7 (13.0)
ORR (95% CI), %	28.1 (13.75, 46.75)	36.4 (17.20, 59.34)	31.5 (19.52, 45.55)
DCR (95% CI), %	90.6 (74.98, 98.02)	81.8 (59.72, 94.81)	87 (75.10, 94.63)



Outstanding therapeutic effect: ORR=31.5%, mPFS=7.5m, the median OS was not reached.



Manageable safety profile: The most common TRAEs were hematological toxicity: white blood cell count decreased, neutrophil count decreased, and platelet count decreased.

01

Financial Highlights





Financial Highlights

Unit: RMB' M

	1Q26	1Q25	Change
Revenue¹	6,465	7,015	-7.8%
Revenue (excluding the licence fee income)	6,319	6,297	+0.4%
Gross profit	4,268	4,705	-9.3%
Gross profit margin	66.0%	67.1%	-1.1 pp
R&D expenses	1,403	1,302	+7.7%
Reported profit attributable to shareholders of the Company	860	1,478	-41.8%
Reported profit attributable to shareholders of the Company (excluding the impact of licence fee income)	736	794	-7.3%
Underlying profit attributable to shareholders of the Company²	842	1,411	-40.3%
Basic earnings per share (RMB cents)			
Based on reported profit attributable to shareholders of the Company	7.54	12.91	-41.6%

Note1: The book-in of licence fee income fluctuates between quarters. In 1Q26, the book-in of licence fee income was relatively low, at 146 million RMB (compared to 718 million RMB in 1Q25).

Excluding the licence fee, the total revenue of 1Q26 was 6.319 billion RMB, with a yoy increase of 0.4% and a qoq increase of 7.7%.

Note2: Underlying profit attributable to shareholders of the Company, a non-HKFRS Accounting standards measure, represents reported profit attributable to shareholders of the Company before taking into account the fair value changes on financial assets measured at fair value through profit or loss and employee share-based compensation expense.



Revenue

Revenue by product category

Unit: RMB' M

	1Q26	1Q25	Change
Finished drugs	5,224	5,500	-5.0%
Bulk vitamin C	494	608	-18.7%
Bulk antibiotics	302	464	-35.0%
Functional food and others	445	443	+0.5%



Revenue by therapeutic area

	1Q26	1Q25	Change
Nervous system	2,331	1,908	+22.2%
Oncology	565	552	+2.3%
Anti-infectives	838	922	-9.0%
Cardiovascular	538	411	+30.8%
Respiratory system	271	326	-16.7%
Digestion & metabolism	248	299	-17.0%
Other products	287	364	-21.3%
Licence fee	146	718	-79.7%

Note: Certain percentage changes of financial figures contained in this material are calculated based on the corresponding financial figures in RMB for two periods/years, rounded to the nearest thousand. Therefore, the percentage changes listed in certain tables may differ from those calculated based on the financial figures in RMB for two periods/years, which are presented in million.



Operating Profit

Unit: RMB' M

	1Q26	1Q25	Change	1Q26 OPM	1Q25 OPM	Change
Finished drugs	1,024	1,394	-26.5%	19.6%	25.3%	-5.7 pp
Bulk vitamin C	6	98	-94.1%	1.2%	16.2%	-15.0 pp
Bulk antibiotics	37	91	-59.4%	12.2%	19.6%	-7.4 pp
Functional Food and Others	36	81	-55.6%	8.1%	18.4%	-10.3 pp

Note: Certain percentage changes of financial figures contained in this material are calculated based on the corresponding financial figures in RMB for two periods/years, rounded to the nearest thousand. Therefore, the percentage changes listed in certain tables may differ from those calculated based on the financial figures in RMB for two periods/years, which are presented in million.

02

R & D Pipeline





R&D Overview



- 5 R&D centres located in China & the U.S.
- Approx. 200 Innovative drugs and new formulations

- 8 national science & technology qualifications
- 2 national key labs
- 8 innovative R&D platforms

- 2759 patent applications
- 1076 patents authorised

- 93 national science and technology projects
- 9 national awards



8 Major R&D Technology Platforms

Nanoparticle Formulation Technology Platform




- Mitoxantrone hydrochloride liposomes
- Docetaxel for injection (albumin-bound)
- Irinotecan liposomes
- Sirolimus for injection (albumin-bound)

Vaccine Technology Platform




- Covid-19 mRNA vaccine
- Preventive vaccines such as VZV mRNA
- Therapeutic vaccines such as HPV mRNA

Small Interfering RNA (SiRNA) Technology Platform



- PCSK9 SiRNA
- AGT SiRNA
- Lp(a) SiRNA
- C5 SiRNA

Antibody-Drug Conjugate (ADC) Technology Platform




- EGFR ADC
- ROR1 ADC
- B7-H3 ADC
- Nectin-4 ADC

Antibody/Fusion Protein Technology Platform




- JMT203 (GFRAL)
- JMT106 (GPC3/IFN α)
- JMT206 (ACTRIIA/IIIB)
- SYS6090 (PD-1/IL-15)

Cell Therapy Technology Platform




- SYS6020 (BCMA CAR-T)
- SYS6063 (CD19/BCMA CAR-T)
- SYS6055 (CD19 CAR-T)

Small Molecule Innovative Drug Technology Platform



- Shanzeping (DPP-4)
- SYHX1901 (JAK/TYK)
- SYH2071 (Lp(a))

Long-Acting Injectable Technology Platform



- Octreotide long-acting injection
- Paliperidone palmitate injection
- Semaglutide long-acting injection
- Leuprorelin Extended release Injection

Note : only shows the representative products on each platform

Remarkable Success of the R&D Pipeline

Expected Launch 2026-2028 (In plan) **30+**

✓ **3** has completed

Launched 2021-2025

- Anfulike
- Duoenda
- Duentai
- Jinlitai
- Mingfule (AIS)
- Enyitan
- Enshuxing
- Ansulike
- Meiluotai
- Shanzeping

Expected Launch 2026 (In plan)

- | | |
|--|---|
| <p>Clevidipine injectable emulsion ✓
Acute hypertension crisis</p> <p>Anbenitamab injection (KN026)
≥2L HER2+ advanced gastric cancer</p> <p>Paclitaxel albumin-bound particles (rapid suspension)
Advanced breast cancer</p> <p>Paliperidone palmitate injection (1M)
Schizophrenia</p> <p>Aripiprazole injection ✓
Preventing postoperative nausea and vomiting in adults</p> | <p>Ulsinumab
Plaque psoriasis</p> <p>Batoclimab (introduced)
Myasthenia gravis</p> <p>Pregabalin extended-release tablets
Diabetic peripheral neuropathic pain</p> <p>Amphotericin B liposomes (Europe) ✓</p> <p>TG103 injection
Obesity</p> |
|--|---|
-

Expected Launch 2027-2028 (In plan)

- | | |
|--|---|
| <p>Semaglutide injection
T2DM
Obesity</p> <p>Pertuzumab
Neoadjuvant treatment for HER2+ breast cancer</p> <p>TG103 injection
T2DM</p> <p>Anbenitamab injection (KN026)
Neoadjuvant treatment for HER2+ breast cancer
1L HER2+ breast cancer</p> <p>Sirolimus (albumin-bound)
Malignant PEComa
≥ 2L HR+HER2 - breast cancer</p> <p>Dexmedetomidine bupropion tablets (extended-release)
MDD</p> <p>Valsartan and lisinopril maleate tablets
Hypertension</p> | <p>SYS6010
2L EGFRmut NSCLC</p> <p>DP303c
≥2L HER2+ breast cancer</p> <p>Secukinumab
Moderate to severe plaque-type psoriasis</p> <p>Anbenitamab repodatecan (JSKN003)
2L/3L HER2 Low expression breast cancer
≥2L HER2+ breast cancer</p> <p>Paclitaxel albumin-bound particles (rapid suspension) (the U.S.)</p> <p>JMT101
1L EGFRmut NSCLC</p> <p>Ammuxetine hydrochloride enteric-coated tablets
MDD</p> |
|--|---|
-




R&D pipeline – Vaccine, CAR-T

Premier mRNA Delivery Platform

The world's first LNP Ex vivo CAR-T with clinical approval, and China's first in vivo CAR-T granted clinical IND.

mRNA

Preventive → Therapeutic vaccine




Major candidates	Target	Type	Treatment plan	Phase I	Phase II	Phase III	Launch
Duentai	BA.5 Variant strain	Preventive vaccine	Monotherapy	Incorporate for emergency use			★
Duentai 2	XBB1.5/BQ.1 Variant strain	Preventive vaccine	Monotherapy	Incorporate for emergency use			★
SYS6017	VZV mRNA	Preventive vaccine	Monotherapy	Prevention of herpes zoster virus infection			
SYS6026	HPV mRNA	Therapeutic vaccine	Monotherapy	HPV 16/18 type-related HSIL			
			combined SG001	Advanced solid tumors			
SYS6020	BCMA CAR-T	Ex vivo CAR-T	Monotherapy	SLE			
				MG			
SYS6055	CD19 CAR-T	In vivo CAR-T	Monotherapy	B-cell lymphoma			

R&D pipeline – SiRNA Series Products

5 assets in clinical development, leading China in both pipeline quantity and development progress.

Targeted delivery to the eyes, lungs, fat, and muscles has been achieved, enabling a broader range of indications.



Major candidates	Target	Type	Treatment plan	Phase I	Phase II	Phase III	NDA
SYH2053	PCSK9	SiRNA	Combined statins	Primary hypercholesterolemia and mixed dyslipidemia			
			Monotherapy	Primary hypercholesterolemia and mixed dyslipidemia			
			Combined statins	Heterozygous familial hypercholesterolemia			
SYH2068	LP(a)	SiRNA	Monotherapy	Hyperlipoproteinemia(a)			
SYH2062	AGT	SiRNA	Monotherapy	Hypertension			
SYH2070*	ANGPTL3	SiRNA	Monotherapy	Hyperlipidemia			
SYH2061*	C5	SiRNA	Monotherapy	Complement-related nephropathy			

* approval for the U.S. & China



R&D Pipeline – Biological Agents

4 commercialized, **6** BLA filed, **11** under pivotal trial stage -- Including various forms of drugs such as antibody drugs, cell therapies, and ADCs

	Major candidates	Target	Type	Treatment plan	Phase I	Phase II	Phase III	NDA/BLA	Launch
Immunity	Omalizumab	IgE	Biosimilar	Monotherapy	Chronic spontaneous urticaria				★
				Monotherapy	Moderate to severe persistent allergic asthma				★
	Ulsinumab	IL-12/IL-23	Biosimilar	Monotherapy	Plaque psoriasis				
	Batoclimab	FcRn	mAb	Monotherapy	Myasthenia Gravis				
	Secukinumab	IL-17A	Biosimilar	Monotherapy	Moderate to severe plaque-type psoriasis				
	Dupilumab	IL-4Rα	Biosimilar	Monotherapy	Atopic Dermatitis				
	SYS6093 (CM326)	TSLP	mAb	Monotherapy	Moderate to severe asthma				
				Monotherapy	Chronic sinusitis with nasal polyps				
Monotherapy				Moderate to very severe COPD					
Endocrine Metabolism	TG103 injection	GLP-1	Fusion Protein	Monotherapy	Obesity				
				Monotherapy	T2DM				
				Combined Metformin	T2DM				
	Semaglutide injection (weekly)	GLP-1	Polypeptide	Monotherapy	T2DM				
				Monotherapy	Obesity				
	JMT202*	FGFR1c/βklotho	mAb	Monotherapy	Hypertriglyceridemia				
	JMT206*	ACTRIIA/IIB	mAb	Monotherapy	Weight management				
	SYS2069*	GLP-1/GIP	Polypeptide	Monotherapy	Weight management				
SYH2082*	GLP-1/GIP	Polypeptide	Monotherapy	Weight management					
Others	JMT601*	CD20/CD47	BsAb	Monotherapy	Membranous Nephropathy				

* approval for the U.S. & China 18



R&D Pipeline – Biological Agents

	Major candidates	Target	Type	Treatment plan	Phase I	Phase II	Phase III	NDA/BLA	Launch
Oncology	JMT103	RANKL	mAb	Monotherapy	Osteoclastoma				★
				Monotherapy vs Zoledronic acid	Malignant solid tumor bone metastasis				
	SYSA1802	PD-1	mAb	Monotherapy	Platinum-resistant PD-L1 positive advanced cervical cancer				★
				Combined chemotherapy±Bevacizumab	1L PD-L1 positive advanced cervical cancer				
	Anbenitamab injection (KN026)	HER2	BsAb	Combined chemotherapy vs chemotherapy	≥2L HER2+ advanced gastric cancer				
				Combined HB1801 vs HP+Docetaxel	1L HER2+ breast cancer				
				Combined HB1801±Carboplatin vs HP+Docetaxel±Carboplatin	Neoadjuvant treatment for HER2+ breast cancer				
				Combined chemotherapy±SG001 vs Trastuzumab+chemotherapy±Pembrolizumab	1L HER2+ advanced gastric cancer				
				Combined HB1801+chemotherapy vs HP+chemotherapy	Adjuvant treatment for HER2+ breast cancer				
	Pertuzumab	HER2	Biosimilar	Combined Trastuzumab + Docetaxel	Neoadjuvant treatment for HER2+ breast cancer				
	JMT101	EGFR	mAb	Combined Osimertinib vs Cisplatin + Pemetrexed	1L EGFR Ex20ins NSCLC				
				Combined Irinotecan vs SOC	≥3L colorectal cancer				
Combined Osimertinib vs Osimertinib				1L EGFRmut NSCLC					
JMT203*	GFRAL	mAb	Monotherapy	Tumor cachexia					
JMT106*	GPC3&IFN	BsAb	Monotherapy	Advanced solid tumors					

Note: HP=Trastuzumab + Pertuzumab

* approval for the U.S. & China



R&D Pipeline – Biological Agents

	Major candidates	Target	Type	Treatment plan	Phase I	Phase II	Phase III	NDA/BLA	Launch	
Oncology	Anbenitamab repodatecan (JSKN003)	HER2	ADC	Monotherapy vs T-DM1	≥2L HER2+ breast cancer					
				Monotherapy vs Chemotherapy	2L/3L HER2 Low expression breast cancer					
				Monotherapy vs Chemotherapy	≥3L HER2+ advanced colorectal cancer					
				Monotherapy vs Chemotherapy	Platinum-resistant ovarian cancer					
	DP303c	HER2	ADC	Monotherapy vs T-DM1	≥2L HER2+ breast cancer					
	SYS6010*	EGFR	ADC	Monotherapy vs Platinum-based chemotherapy	2L EGFRmut NSCLC					
				Monotherapy vs Chemotherapy	2L ESCC					
				Combined Osimertinib vs SOC	1L EGFRmut NSCLC					
				Monotherapy vs Chemotherapy	2L EGFRwt Nsq-NSCLC					
				Monotherapy vs Chemotherapy	≥2L HER2-EGFR+advanced breast cancer					
	SYS6002*	Nectin-4	ADC	Monotherapy	≥2L Cervical cancer					
	SYS6043*	B7-H3	ADC	Monotherapy	Advanced solid tumors					
				Combined Sulurelin mAb±platinum	Advanced solid tumors					
	SYS6023*	HER3	ADC	Monotherapy	Advanced solid tumors					
	SYS6041*	FRα	ADC	Monotherapy	Advanced solid tumors					
	SYS6040*	DLL3	ADC	Monotherapy	Advanced solid tumors					
SYS6090*	PD-1/IL-15	Dual-Functional Fusion Protein	Monotherapy	Advanced solid tumors						

* approval for the U.S. & China 20



R&D Pipeline – New Formulations

5 commercialized, 2 NDA filed, 5 under pivotal trial stage -- Including various forms of drugs such as liposomes, albumin and nanocrystals

	Major candidates	Type	Treatment plan	Phase I	Phase II	Phase III	NDA/BLA	Launch
Oncology	Mitoxantrone hydrochloride liposome injection	New formulation	Monotherapy	PTCL				★
	Irinotecan liposome injection*	New formulation	Combined treatment	1L pancreatic cancer ; 2L pancreatic cancer				★
	Amphotericin B Liposome*	New formulation	Monotherapy	Treatment of systemic and / or deep fungal infections; Empirical treatment for suspected fungal infections (China/Europe)				★
	Paclitaxel albumin-bound particles (rapid suspension) *	New formulation	Monotherapy	Advanced breast cancer				
	Sirolimus (albumin-bound)	New formulation	Monotherapy	Malignant PEComa				
			Combined Fulvestrant vs Fulvestrant	≥ 2L HR+HER2- breast cancer				
	Docetaxel (albumin- bound)	New formulation	Combined HP vs Docetaxel+HP	1L HER2+ Breast cancer				
	Daunorubicin cytarabine liposome for injection	New formulation	Monotherapy	Initial therapy in elderly patients with high-risk secondary AML				
	Paclitaxel cationic liposome for injection	New formulation	Combined treatment	Liver metastasis of colorectal cancer (arterial infusion)				
Leuprorelin extended-release injection	New formulation	Monotherapy	Prostate cancer					
Non-oncology	Clevidipine injectable emulsion	New formulation	Monotherapy	Acute Hypertension Crisis				★
	Apirpitan injection	New formulation	Monotherapy	Preventing postoperative nausea and vomiting in adults				★
	Paliperidone palmitate injection (1M)	New formulation	Monotherapy	Schizophrenia				
	Long-acting octreotide injection	New formulation	Monotherapy	Acromegaly				
			Monotherapy	Postoperative adjuvant therapy for pancreatic neuroendocrine tumors				


Note: HP=Trastuzumab + Pertuzumab

* approval for the U.S. & China



R&D Pipeline – Small Molecule Drugs

1 commercialized, 1 NDA filed, 5 under pivotal trial stage

	Major candidates	Target	Type	Treatment plan	Phase I	Phase II	Phase III	NDA/BLA	Launch
Oncology	SYHA1813	VEGFR/CSF1R	Small molecule	Monotherapy	Recurrent or progressive high-grade meningioma				
				Monotherapy	Adjuvant therapy for SCLC				
	SYH2043	CDK2/4/6	Small molecule	Monotherapy	Breast cancer				
	SYH2045	PRMT5	Small molecule	Monotherapy	Advanced tumor				
Non-oncology	Shanzeping	DPP-4	Small molecule	Monotherapy	T2DM 				
				Monotherapy	T2DM - compound preparation				
	Pregabalin extended-release tablets	GABA analogue	Small molecule	Monotherapy	Diabetic peripheral neuropathic pain				
	SYHX1901	JAK&TYK Inhibitor	Small molecule	Monotherapy	Moderate to severe plaque-type psoriasis				
				Monotherapy	Severe alopecia areata				
	Valsartan levoamlodipine maleate tablets	Angiotensin II receptor antagonist	Small molecule	Monotherapy	Hypertension				
	Ammuxetine hydrochloride enteric-coated tablets	SNRI	Small molecule	Monotherapy	MDD				
	Dexmedetomidine bupropion tablets (extended-release)	NMDA receptor antagonist	Small molecule	Monotherapy	MDD				
	SYH2059*	PED4B	Small molecule	Monotherapy	Idiopathic Pulmonary Fibrosis (IPF)				
	SYH2046*	undisclosed	Small molecule	Monotherapy	Heart failure after acute myocardial infarction				
	SYH2056*	5-HT ₂ A	Small molecule	Monotherapy	MDD				
	SYH2072*	Aldosterone synthase inhibitor	Small molecule	Monotherapy	Uncontrolled hypertension				



Common Generics Launch Plan

20+ generic drugs are expected to be launched during the years 2026-2027; Additionally, approximately **10** projects are currently in the pharmaceutical research phase.

2026

Iron sucrose injection

Others

Tandospirone citrate tablets

Mental nerve

Lansoprazole enteric-coated capsules

Digestion & Metabolism ✓

Esomeprazole magnesium enteric-coated granule suspension

Digestion & Metabolism

Budesonide enteric-coated capsules

Autoimmunity ✓

Bripiprazole tablets

Mental nerve

Cyclosporine soft capsules

Autoimmunity

Pregabalin extended-release tablets

Mental nerve

Englecanide metformin extended-release tablets

Digestion & Metabolism

SGLT2 and metformin extended-release tablets

Digestion & Metabolism

Upatinib extended-release tablets

Autoimmunity

Rivaroxaban

Cardiovascular and cerebrovascular

2027

Clopidogrel and aspirin tablets

Cardiovascular and cerebrovascular

Nematrevi / Ritonavir tablets

Anti-infective

Mesalazine extended-release granules

Autoimmunity

Diazepam nasal spray

Mental nerve

Dapagliflozin metformin extended-release tablets

Digestion & Metabolism

Idarucabtaglucol injection concentrated solution

Mental nerve

Dextromethorphan and bupropion extended-release tablets

Mental nerve

Sulfaspiroside isavancin for injection

Anti-infective

.....

✓ Completed

03

ESG





Building a Sustainable Business, Aim to Become an ESG Leader in Pharmaceutical Industry

2025 Key Environmental Protection Data

*The emission reduction target is based on the emission in 2017

Greenhouse gas emissions per unit of revenue
↓ 50.0%

Total energy consumption per unit of revenue
↓ 64.0%

The amount of hazardous waste discharged per unit of revenue
↓ 80.0%


The amount of harmless waste discharged per unit of revenue
↓ 32.0%

Significant cost savings in carrying out energy-saving renovations and introducing new highly efficient energy-saving equipment exceed


The investment in water conservation and water recycling projects exceed

30 million RMB

1 million RMB



Received MSCI ESG Rating of A for 5 consecutive years



Social assistance project in 2025

- Cumulative donation expenditure: 61.55 million RMB
- Employee assistance: 105,880 people
- Volunteer service duration: 95,469 hours

- ◆ Ouyi, NBP, CSPC Innovation, Yinhu and Taizhou factory have been recognized by the Ministry of Industry and Information Technology as "National Level Green Factories"
- ◆ Weisheng and Shengxue are "Provincial Level Green Factories"
- ◆ Achieved "Five Zeros and One Low": zero cases of death, serious injuries, multiple injuries, occupational disease and poisoning incident as well as low incident rate of minor injuries

04

Appendix: Product Overview





Business Development Drives Global Expansion

2025

In 2025, **4** BD transactions have been completed. The total licence fee is **9.71** billion US dollars , including **260** million US dollars upfront payment.

1



SYS6005 / ROR1 ADC

Development and commercialization in overseas licensing areas
Upfront payment: \$15 million
Maximum potential milestone payment: \$1.225 billion

2



Irinotecan liposome Injection

USA commercialization
Upfront payment: \$15 million
Maximum potential milestone payment: \$1.05 billion

3



Strategic collaboration based on AI platform

Global development and commercialization
Upfront payment: \$110 million
Maximum potential milestone payment: \$5.22 billion

4



SYH2086 / GLP-1

Global development and commercialization
Upfront payment: \$120 million
Maximum potential milestone payment: \$1.955 billion

2026



18.5 billion US dollars – The largest-ever licensing deal by a Chinese pharmaceutical company



Strategic collaboration based on long-acting and peptide platform


Development and commercialization in overseas licensing areas
Upfront payment: \$1.2 billion
Maximum potential milestone payment: \$17.3 billion

Agreement includes eight programs, including a clinical-ready asset (SYH2082), plus access to advanced AI-driven peptide drug discovery platform and innovative monthly dosing technology.

Trading model has become diversified, from out-licensing of single product to platform based strategic collaboration.



Finished Drugs Overview by Therapeutic Areas



Nervous system

- Major products: NBP, Mingfule-AIS (recombinant human TNK tissue-type plasminogen activator for injection), Shuanling, Enliwei (lacosamide injection, lacosamide tablets), Enxi (Prampipexole Dihydrochloride Tablets), Oushuan (paliperidone Extended-release tablets) and Oulaining etc.

Oncology

- Major products: Jinyouli, Duomeisu, Keaili, Duoenyi (irinotecan hydrochloride liposome injection), Duoenda, Geruite (lenvatinib mesilate capsules), Enshuxing(PD-1) and Jinlitai (Narlumosbart injection) etc.

Anti-infective

- Major products: Ansulike, Anfulike, Weihong (azithromycin tablets/capsules/enteric-coated tablets, azithromycin for injection), Shuluoke (meropenem for injection), Nuomoling (amoxicillin capsules), Xianqu (ceftriaxone sodium for injection), Xianwu (cefazolin sodium for injection) and Oujian (Cefixime Capsules) etc.

Cardio-vascular

- Major products: Xuanning, Encun (clopidogrel bisulfate tablets), Abikang (aspirin enteric-coated tablets), Yishuning (nifedipine controlled-release tablets), Mingfule-AMI, Daxinning (dronedarone hydrochloride tablets) and Meiluolin (ticagrelor tablets) etc.

Respiratory system

- Major products: Yiluoda (nintedanib capsules), Qixin (oseltamivir phosphate capsules), Nuoyian (montelukast sodium tablets/chewable tablets), Qixiao (arbidol hydrochloride tablets), Zhongnuolike (ambroxol hydrochloride oral solution), Zhongnuoping (ambroxol hydrochloride extended-release tablets) and Enyitan (Omalizumab for injection) etc.

Digestion & metabolism

- Major products: Linmeixin (glimepiride dispersible tablets), Shuanglexin (metformin hydrochloride tablets/extended release tablets), Xinweiping (acarbose tablets), Obeituo (Esomeprazole magnesium enteric-coated capsules) and Debixin (omeprazole enteric capsules/tablets/injections) etc.

Others

- Major products: Qimaite(Tramadol Hydrochloride Tablets), Oubida (apgumilast tablets), Gujie (tofacitib citrate extended-release tablets), Gubang (alendronate sodium tablets/enteric tablets), Xianpai (omeprazole sodium for injection), Shanzeping and Meiluotai etc.



Innovation achievements: Overview of Key products

Innovative drugs

New Formulations and Biosimilar Drugs

NBP



Butylphthalide soft capsules and injections

Mingfule



Recombinant human TNK tissue-type plasminogen activator for injection

Jinyouli



PEG-rhG-CSF injection

Duomeisu



Doxorubicin Hydrochloride liposome injection

Duoenyi



Irinotecan hydrochloride liposome injection

Xuanning



Levamlodipine maleate tablets and dispersible tablets

Duoenda



Mitoxantrone hydrochloride liposome injection

Duentai



COVID-19 mRNA vaccine

Ansulike



Amphotericin B Liposome for Injection

Anfulike



Amphotericin B cholesteryl sulfate complex for injection

Enshuxing



PD-1 inhibitor Enlangsumab Injection

Jinlitai



Narlumosbart for injection

Shanzeping



Prusoglipitin tablets

Enyitan



Omalizumab for Injection

Meiluotai



Meloxicam Injection (III)



E-mail Address of CSPC IR Team:

ir@cspc.cn

IR official website:



Thanks!